Bristol's Opdivo Suffers Rare, But Unsurprising, Rejection By FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Data were lacking for Bristol's PD-1 inhibitor as monotherapy in first-line BRAF-mutant melanoma, resulting in FDA complete response letter for expanded indication.